ASMB Earnings Date: Nov 9, 2026 (Estimated) — Assembly Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ASMB's next earnings date?
Assembly Biosciences, Inc. (ASMB) is expected to report Q3 2026 earnings on Monday, November 9, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.66 on revenue of $9.1M.
How did ASMB do in its last earnings report?
In its most recent report on Aug 13, 2026 (Q2 2026), Assembly Biosciences, Inc. posted EPS of -$0.20 versus the -$0.72 estimate, a beat of 64.3%. Revenue was $13.4M against a $8.6M estimate. The stock's 1-day post-earnings move was +10.0%.
How much does ASMB stock move after earnings?
ASMB beat EPS estimates in 7 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.8% (up or down) in the day after earnings.
About Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV. The company's development pipeline also features ABI-H3733, which has finished Phase 1a clinical studies, and ABI-4334, currently in pre-clinical assessment for HBV treatment. Assembly Biosciences has forged collaborative partnerships, including agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation, as well as with Antios Therapeutics, Inc., to explore a triple-combination treatment strategy for chronic hepatitis B virus. Additionally, it maintains strategic licensing arrangements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC. Established in 2005, the company was formerly known as Ventrus Biosciences, Inc. before rebranding to Assembly Biosciences, Inc. in June 2014, and its headquarters are located in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-13 | Q2 2026 | -0.72 | -0.20 | +64.29% | $13.4M | ✅ Beat | +10.02% | +11.95% | -3.31% |
| 2026-05-07 | Q1 2026 | -0.66 | -0.54 | +18.18% | $8.2M | ✅ Beat | -3.85% | -2.04% | -27.08% |
| 2026-03-19 | Q4 2025 | -0.71 | 1.30 | +283.10% | $42.5M | ✅ Beat | +3.45% | +4.94% | +2.25% |
| 2025-11-10 | Q3 2025 | -0.59 | -0.72 | -22.03% | $10.8M | ❌ Miss | +3.31% | +13.28% | +11.85% |
| 2025-08-06 | Q2 2025 | -1.73 | -1.33 | +23.12% | $9.6M | ✅ Beat | +9.21% | +27.38% | +22.70% |
| 2025-03-20 | Q4 2024 | -1.75 | -1.57 | +10.29% | $7.4M | ✅ Beat | +2.99% | +1.96% | -7.02% |
| 2024-11-07 | Q3 2024 | -2.02 | -1.51 | +25.25% | $6.8M | ✅ Beat | -4.11% | -2.57% | -4.60% |
| 2024-05-08 | Q1 2024 | -3.24 | -1.66 | +48.77% | $5.8M | ✅ Beat | +1.25% | +13.70% | +11.13% |
Showing last 8 quarters.